title: Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ Cooperative Group, Spain.
abstract: Cisplatin (P) and 5-fluorouracil (5FU) have demonstrated activity for the treatment of squamous cell carcinoma of the esophagus. Previous studies have shown that leucovorin (L) may potentiate the antitumoral activity of 5FU, so we tested the combination P-5FU-L in 31 patients with inoperable squamous cell esophageal carcinoma. Chemotherapy consisted of P 20 mg/m2 in 4 h, followed by L 200 mg/m2 in 2 h and 5FU 600 mg/m2 in 18 h. This schedule was repeated for 5 days every 4 weeks. The treatment plan included three courses of chemotherapy followed by radiotherapy. The overall response rate was 58% (95% CI = 39-76%), with one complete remission (3%), and 61% of patients reported an improvement in dysphagia. Gastrointestinal toxicity was the main side effect: grade 3-4 mucositis appeared in 19% of patients, grade 3-4 nausea/vomiting in 13%, and grade 3-4 diarrhea in 6.5%. There was one toxic death caused by neutropenia and sepsis. Nineteen patients received local radiotherapy after chemotherapy, which increased the overall response rate to 63% (5% complete responses). Dysphagia improved in 75% of them. The median survival for all patients was 11 months. This study shows that sequential therapy with P-5FU-L and radiotherapy achieves a high response rate as well as adequate symptomatic relief in patients with inoperable esophageal cancer. The results justify further evaluation of P-5FU-L in patients with earlier-stage disease.
authors.affiliation: Medical Oncology Service, La Paz Hospital, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Feliu
authors.forename: M
authors.initials: M
authors.lastname: González Barón
authors.forename: C
authors.initials: C
authors.lastname: García Girón
authors.forename: E
authors.initials: E
authors.lastname: Espinosa
authors.forename: J M
authors.initials: JM
authors.lastname: Vicent
authors.forename: J
authors.initials: J
authors.lastname: Gómez Navarro
authors.forename: A
authors.initials: A
authors.lastname: Berrocal
authors.forename: A
authors.initials: A
authors.lastname: Ordóñez
authors.forename: Y
authors.initials: Y
authors.lastname: Vilches
authors.forename: J
authors.initials: J
authors.lastname: de Castro
authors.forename: J
authors.initials: J
authors.lastname: Díaz
mesh_terms: D000328:Adult; D000368:Aged; D000931:Antidotes / Q000008:administration & dosage*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D003680:Deglutition Disorders / Q000517:prevention & control; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000187:drug effects; D009325:Nausea / Q000139:chemically induced; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D015996:Survival Rate; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000931:Antidotes; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D013940:Thymidylate Synthase; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil